Sofia Romero-Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sofia Romero-Santos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra De-La-Torre
Universidad del Rosario
3 shared publications - Carlos Cifuentes-González
National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore
3 shared publications - Germán Mejía-Salgado
Facultad de Ciencias de la Salud, Universidad Autónoma de Bucaramanga - UNAB, Bucaramanga, Colombia
2 shared publications - Ana María Barragán
Public Health Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
1 shared publication - Ariel Schlaen
Department of Ophthalmology, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina
1 shared publication Cristobal Couto
Uveitis Section, Ophthalmology Department, Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
1 shared publication
Latest Publications
- 29 July 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (10) , 2388-2404
Clinical Characteristics of Ocular Mucous Membrane Pemphigoid: A Systematic Review and Meta-Analysis
Mucous membrane pemphigoid (MMP) is a systemic, immune-mediated, chronic disease characterized by the development of subepithelial blisters due to the presence of autoantibodies directed against st...
- 29 July 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (10) , 2388-2404
Clinical Characteristics of Ocular Mucous Membrane Pemphigoid: A Systematic Review and Meta-Analysis
Mucous membrane pemphigoid (MMP) is a systemic, immune-mediated, chronic disease characterized by the development of subepithelial blisters due to the presence of autoantibodies directed against st...
- 9 April 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (9) , 1-7
Systemic and Bilateral Severe Ocular Toxoplasmosis Resembling Autoimmune Phenomena: A Case Report
PurposeTo present an atypical case of severe bilateral ocular toxoplasmosis with systemic involvement that initially mimicked an autoimmune etiology, posing challenges to its diagnosis and treatment.Case ReportA 39-year-old immunocompetent male was admitted to the hospital due to a presumed pulmonary thromboembolism concomitant with an abrupt onset of vision loss. Initial differential diagnoses included antiphospholipid syndrome and systemic lupus erythematosus, prompting the administration of corticosteroid pulses and rituximab. Despite observing a partial systemic response, there was no improvement in visual acuity. Subsequent aqueous humor polymerase chain reaction confirmed Toxoplasma gondii infection, leading to the introduction of oral antibiotic therapy. The patient's condition showed a partially favorable response; however, the treatment could not reverse the permanent retinal damage.Conclusion and importanceThis case underscores the importance of ruling out an infectious etiology in all cases of uveitis. Additionally, it alerts clinicians to the possibility that elevated positive autoantibodies may result from a severe inflammatory reaction caused by pathogens rather than an autoimmune or autoinflammatory disease, particularly in instances of poor treatment response or atypical clinical presentation.
- 9 April 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (9) , 1-7
Systemic and Bilateral Severe Ocular Toxoplasmosis Resembling Autoimmune Phenomena: A Case Report
PurposeTo present an atypical case of severe bilateral ocular toxoplasmosis with systemic involvement that initially mimicked an autoimmune etiology, posing challenges to its diagnosis and treatment.Case ReportA 39-year-old immunocompetent male was admitted to the hospital due to a presumed pulmonary thromboembolism concomitant with an abrupt onset of vision loss. Initial differential diagnoses included antiphospholipid syndrome and systemic lupus erythematosus, prompting the administration of corticosteroid pulses and rituximab. Despite observing a partial systemic response, there was no improvement in visual acuity. Subsequent aqueous humor polymerase chain reaction confirmed Toxoplasma gondii infection, leading to the introduction of oral antibiotic therapy. The patient's condition showed a partially favorable response; however, the treatment could not reverse the permanent retinal damage.Conclusion and importanceThis case underscores the importance of ruling out an infectious etiology in all cases of uveitis. Additionally, it alerts clinicians to the possibility that elevated positive autoantibodies may result from a severe inflammatory reaction caused by pathogens rather than an autoimmune or autoinflammatory disease, particularly in instances of poor treatment response or atypical clinical presentation.
- 10 January 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (8) , 1882-1887
Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients: A Case Report and Literature Review
PurposeTo report two cases of ibrutinib-related uveitis and review the literature to date.MethodsWe report two cases of ibrutinib-related uveitis using CARE guidelines and review the cases reported in the literature.ResultsCase 1) A 55-year-old female with recurrent primary central nervous system lymphoma presented with bilateral decreased visual acuity, photophobia, and floaters that started one month after initiating oral treatment with ibrutinib. Chronic non-granulomatous bilateral anterior-intermediate uveitis with macular edema was identified. Secondary causes were ruled out, and a presumptive diagnosis of ibrutinib-related uveitis was made. Case 2) A 57-year-old female with Waldenstrom macroglobulinemia who was treated with ibrutinib for two years presented with bilateral blurred vision, photophobia, red eyes, and floaters. A diagnosis of non-granulomatous, noninfectious panuveitis with bilateral cystoid macular edema was made. Secondary causes were ruled out, and ibrutinib toxicity was the most likely cause.ConclusionIbrutinib-related uveitis is a novel and under-diagnosed clinical entity. The most frequent clinical presentation in the literature is bilateral, non-granulomatous, anterior, and intermediate uveitis. Macular edema is a frequent complication. Uveitis usually requires topical treatment and the suspension of ibrutinib. Switching to second-generation Bruton tyrosine kinase inhibitors is proposed as a potential therapeutic alternative.
- 10 January 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (8) , 1882-1887
Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients: A Case Report and Literature Review
PurposeTo report two cases of ibrutinib-related uveitis and review the literature to date.MethodsWe report two cases of ibrutinib-related uveitis using CARE guidelines and review the cases reported in the literature.ResultsCase 1) A 55-year-old female with recurrent primary central nervous system lymphoma presented with bilateral decreased visual acuity, photophobia, and floaters that started one month after initiating oral treatment with ibrutinib. Chronic non-granulomatous bilateral anterior-intermediate uveitis with macular edema was identified. Secondary causes were ruled out, and a presumptive diagnosis of ibrutinib-related uveitis was made. Case 2) A 57-year-old female with Waldenstrom macroglobulinemia who was treated with ibrutinib for two years presented with bilateral blurred vision, photophobia, red eyes, and floaters. A diagnosis of non-granulomatous, noninfectious panuveitis with bilateral cystoid macular edema was made. Secondary causes were ruled out, and ibrutinib toxicity was the most likely cause.ConclusionIbrutinib-related uveitis is a novel and under-diagnosed clinical entity. The most frequent clinical presentation in the literature is bilateral, non-granulomatous, anterior, and intermediate uveitis. Macular edema is a frequent complication. Uveitis usually requires topical treatment and the suspension of ibrutinib. Switching to second-generation Bruton tyrosine kinase inhibitors is proposed as a potential therapeutic alternative.